The red part is the recognition epitope as shown.
1. The AFfirm™ family of mouse monoclonal antibodies are generated from specific peptide antigens. There are significant advantages over the 80% of recombinant protein antigens on the market
- The specificity is highly guaranteed and the location of the recognized protein is more defined.
- Homology prediction for antibody recognition epitope and target protein is more informative
- In contrast to the time-consuming and laborious determination of antibody epitopes (there are currently less than 300 types of mouse monoclonal antibodies that have been used worldwide to determine antigenic epitopes. In a sense, the mouse monoclonal antibodies on the market do not know the exact location of the recognized proteins), AFfirm family monoclonal antibodies are born with a clear epitope recognition.
2. Based on flow-sorting technology, we are able to screen monoclonal cell lines with the highest affinity for the AFfirm™ family of monoclonal antibodies. This can be 10-50 times higher than traditional mouse monoclonal antibodies (dilution 1:10,000, 10s).
3. The R&D cycle for the AFfirm family of monoclonal antibodies has been significantly shortened. Traditional monoclonal screening steps are cumbersome and tedious, and multiple subclones are time consuming and laborious. By using the high throughput of flow sorting, it takes only one minute to screen a plate of 96-well monoclonal cells, greatly improving efficiency.
4. Endogenous WB has been used as the qualification criteria for the full range of AFfirm™ monoclonal antibodies. Compared to overexpressed and recombinant protein samples, endogenous detection is the best standard.
5. The full range of AFfirm™ antibodies are available in customized components, supplied in mg-grade and g-grade.
